Extension Study to Study PQ-110-001 (NCT03140969)

Phase 1

Terminated

Conditions: Neurologic Manifestations
Eye Diseases, Hereditary
Retinal Disease
Blindness
Leber Congenital Amaurosis
Sensation Disorders
Vision Disorders
Eye Diseases
Eye Disorders Congenital
Leber Congenital Amaurosis 10

Brief Summary: Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject. Study PQ-110-002 will provide long-term safety, tolerability, pharmacokinetic (PK), and efficacy data of QR-110.

Detailed Description: Subjects completing participation in study PQ-110-001 (EudraCT 2017-000813-22 / NCT03140969) will be given the opportunity to enroll into the extension study for continued dosing if available data support current and/or future benefits for the subject.

Subjects will be given the opportunity to enroll into this extension study for continued dosing if available data support current and/or future benefits for the subject. The Investigator, in consultation and agreement with the Medical Monitor, will decide on enrollment of each individual subject, as well as on dosing of the first treated eye and treatment initiation of the contralateral eye. Continued subject treatment in this study is desirable, but cannot be guaranteed, since it will depend on the risks and benefit of further treatment on a case-by-case basis, as discussed and agreed upon with the Medical Monitor.

The contralateral eye and the first treated eye will be injected 3 months apart. The injection interval of 3 months between both eyes will limit burden for the subjects, with a 3 month-visit frequency during the course of the study. This between-eye interval could be adapted if safety data are supportive, and for logistic reasons, and in agreement with the Medical Monitor.

The same safety monitoring protocol and efficacy assessments will apply to both eyes.

QR-110 will be administered via intravitreal (IVT) injection.

Recruitment & Eligibility

Inclusion Criteria

Subjects who completed participation in the study PQ-110-001 and who may derive benefit from continued treatment with QR 110, as assessed by the Investigator, in consultation with the Medical Monitor
Persistence of detectable outer nuclear layer (ONL) in the area of the macula in the opinion of the Investigator, as determined by OCT.
Clear ocular media and adequate pupillary dilation to permit good quality retinal imaging, as assessed by the Investigator.
An adult (≥ 18 years) willing and able to provide informed consent for participation OR a minor (6 to < 18 years) with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures, and pediatric subjects able to provide age-appropriate assent for study participation.
Female subjects who have reached menarche and male subjects must either practice true abstinence in accordance with their preferred and usual lifestyle, or agree to use acceptable, highly effective methods of contraception for up to 3 months following their last dose QR-110. Acceptable methods of contraception are defined in the protocol. Women of non-childbearing potential may be included without the use of adequate birth control, provided they meet the criteria in the protocol.

Exclusion Criteria

Any contraindication to IVT injection according to the Investigator's clinical judgment and international guidelines (Avery 2014).
Safety issue during study PQ-110-001 that may compromise subject safety when continued dosing, as determined by the Investigator, and in consultation with the Medical Monitor.
Any ocular or systemic disease or condition (including medications and laboratory test abnormalities) that could compromise subject safety or interfere with assessment of efficacy and safety, as determined by the Investigator and in consultation with the Medical Monitor.
Pregnant or breast-feeding female.

Arm && Interventions

Group	Intervention	Description
Drug QR-110	QR-110	First treated eye: maintenance dose every 6 months, intravitreal administration Contralateral eye: loading dose followed by maintenance dose, every 6 months, intravitreal administration

Primary Outcome Measures

Name	Time	Method
Frequency of Ocular AEs	24 months	Frequency of ocular adverse events (AEs)
Frequency of Non-ocular AEs	24 months	Frequency of non-ocular AEs

Secondary Outcome Measures

Name	Time	Method
Change in OCI	24 months	Change in Oculomotor Instability (OCI)
Change in BCVA in First Treated Eye	24 months	Change in Best Corrected Visual Acuity (BCVA) in First Treated Eye
Change in CVAQ	24 months	Change in Cardiff Visual Ability Questionnaire for Children (CVAQC) score (pediatric subjects)
Change in Mobility Course Score	24 months	Change in Mobility course score
Change in FST Blue	24 months	Change in Full-Field Stimulus Testing (FST) - blue stimuli
Change in VFQ-25	24 months	Change in Visual Function Questionnaire-25 (VFQ-25) score (adult subjects)
Change in PLR	24 months	Change in Pupillary Light Reflex (PLR) (latency and amplitude)
Change in NIRAF	24 months	Change in Near Infrared AutoFluorescence (NIRAF)
Change in FST Red	24 months	Change in Full-Field Stimulus Testing (FST) - red stimuli
Change in Photoreceptor Outer Segment Layer Thickness	24 months	Change in photoreceptor outer segment layer thickness by Optical Coherence Tomography (OCT)
Change in BCVA in Treated Contralateral Eye	24 months	Change in Best Corrected Visual Acuity (BCVA) in Treated Contralateral Eye
Change in BCVA in Non-Treated Contralateral Eye	24 months	Change in Best Corrected Visual Acuity (BCVA) in Non-Treated Contralateral Eye

Locations (3): University of Iowa
🇺🇸
Iowa City, Iowa, United States
Ghent University Hospital and Ghent University
🇧🇪
Ghent, Belgium
Scheie Eye Institute, University of Pennsylvania
🇺🇸
Philadelphia, Pennsylvania, United States